Our latest publication is Repurposing auranofin as a lead candidate for treatment of lymphatic filariasis and onchocerciasis (Bulman CA, Bidlow CM, Lustigman S, Cho-Ngwa F, Williams D, Rascón AA, Tricoche N, Samje M, Bell A, Suzuki B, Lim KC, Supakorndej N, Supakorndej P, Wolfe AR, Knudsen GM, Chen S, Wilson C, Ang KH, Arkin M, Gut J, Franklin C, Marcellino C, McKerrow JH, Debnath A, Sakanari JA. PLoS Negl Trop Dis. 2015 Feb; 9(2):e0003534. A primary goal of the the laboratory is to find compounds that have been approved for human use that can repurposed to treat neglected diseases. In this case, auranophin, a drug designed to be a safer treatment for rheumatoid arthritis was examined as a treatment for two parasitic diseases, lymphatic filariasis and onchocerciasis. Auranofin is of particular interest because it may be an agent that works at the macrofilarial stage as opposed to the microfilarial stage that current drugs such as ivermectin, diethylcarbamazine (DEC), and albendazole treat. The publication can be read here.